Vertex, NASDAQ and VRTX

Canaccord Genuity Upgrades Vertex Pharmaceuticals (VRTX)
Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sell to Hold. Analyst Price Forecast Suggests 10.64% Upside As of January 29,
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top Estimates
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations, with sales up 15.7% year on year to $2.91 billion. The company expects the full year’s revenue to be around $11.
Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $467.00 Price Target at Barclays
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on Tuesday,Benzinga reports.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy.
Vertex Pharmaceuticals EVP Ourania Tatsis sells $142,547 in stock
BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near its 52-week high,
Brokers Issue Forecasts for VRTX Q1 Earnings
Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Vertex ...
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Is VRTX a Portfolio Must Have After Two FDA Nods Ahead of Q4 Earnings?
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza ...
Nasdaq2d
April 4th Options Now Available For Vertex Pharmaceuticals (VRTX)
Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Vertex Pharmaceuticals files automatic mixed securities shelf
EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...
Vertex Q4 Earnings On Deck: Will This Biotech Heavyweight Keep Its Edge?
Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...
Nasdaq3d
VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, missing the Zacks Consensus Estimate of $3.99. The bottom line declined 5.2% ...
Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (INSP), Vertex Pharmaceuticals (VRTX) and Incyte (INCY)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inspire Medical Systems (INSP – Research ...